Literature DB >> 9276614

Silent and multiple mutations in p53 and the question of the hypermutability of tumors.

B S Strauss1.   

Abstract

Published data on TP53 mutations can be used to examine the question of whether generalized hypermutability is a necessary condition for tumorigenesis. Although individual mutations do play an etiologic role in tumor formation, the evidence so far does not make it necessary to assume a general mutability. Silent and multiple mutations in the TP53 data set indicate that a special hypermutability process operates on this gene during the generation of tumors. The percentage of silent p53 mutations observed (3%) is at least 20 times greater than would be expected and indicates hypermutability for this gene. The greater proportion of silent mutations among multiple p53 mutations (10%) indicates that the mutations occur nonselectively. The presence of silent mutations implies that not all mutations observed in tumors have an etiologic role. Analysis of the distribution of tumors with two, three, four and more p53 mutations suggests that mutations in some tumors occur in clusters possibly as a result of 'stuttering' in DNA synthesis. It is argued that the most likely alternative explanations of the data, polymorphism and/or a selective role for silent mutations, are not correct. It remains possible that the hypermutability process is restricted to particular genes or to regions of the genome as, for example, in antibody production. There is a surprising paucity of data on human polymorphism and nucleotide diversity which makes the analysis difficult.

Entities:  

Mesh:

Year:  1997        PMID: 9276614     DOI: 10.1093/carcin/18.8.1445

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  10 in total

Review 1.  Mutation and cancer: the antecedents to our studies of adaptive mutation.

Authors:  J Cairns
Journal:  Genetics       Date:  1998-04       Impact factor: 4.562

Review 2.  Hypermutability in carcinogenesis.

Authors:  B S Strauss
Journal:  Genetics       Date:  1998-04       Impact factor: 4.562

Review 3.  P53 mutations in thyroid carcinoma: tidings from an old foe.

Authors:  N R Farid
Journal:  J Endocrinol Invest       Date:  2001 Jul-Aug       Impact factor: 4.256

4.  Prevalence of somatic alterations in the colorectal cancer cell genome.

Authors:  Tian-Li Wang; Carlo Rago; Natalie Silliman; Janine Ptak; Sanford Markowitz; James K V Willson; Giovanni Parmigiani; Kenneth W Kinzler; Bert Vogelstein; Victor E Velculescu
Journal:  Proc Natl Acad Sci U S A       Date:  2002-02-26       Impact factor: 11.205

5.  Strand asymmetry of CpG transitions as indicator of G1 phase-dependent origin of multiple tumorigenic p53 mutations in stem cells.

Authors:  S N Rodin; A S Rodin
Journal:  Proc Natl Acad Sci U S A       Date:  1998-09-29       Impact factor: 11.205

6.  GT198 Splice Variants Display Dominant-Negative Activities and Are Induced by Inactivating Mutations.

Authors:  Min Peng; Zheqiong Yang; Hao Zhang; Lahcen Jaafar; Guanghu Wang; Min Liu; Hernan Flores-Rozas; Jianming Xu; Nahid F Mivechi; Lan Ko
Journal:  Genes Cancer       Date:  2013-01

7.  Analysis of Tp53 codon 72 polymorphisms, Tp53 mutations, and HPV infection in cutaneous squamous cell carcinomas.

Authors:  Keith R Loeb; Maryam M Asgari; Stephen E Hawes; Qinghua Feng; Joshua E Stern; Mingjun Jiang; Zsolt B Argenyi; Ethel-Michele de Villiers; Nancy B Kiviat
Journal:  PLoS One       Date:  2012-04-24       Impact factor: 3.240

8.  Identification of tumour-associated and germ line p53 mutations in canine mammary cancer.

Authors:  N Veldhoen; J Watterson; M Brash; J Milner
Journal:  Br J Cancer       Date:  1999-10       Impact factor: 7.640

9.  Epidemiology of doublet/multiplet mutations in lung cancers: evidence that a subset arises by chronocoordinate events.

Authors:  Zhenbin Chen; Jinong Feng; Carolyn H Buzin; Steve S Sommer
Journal:  PLoS One       Date:  2008-11-13       Impact factor: 3.240

Review 10.  A clinicopathological review of 33 patients with vulvar melanoma identifies c-KIT as a prognostic marker.

Authors:  Viola A Heinzelmann-Schwarz; Sheri Nixdorf; Mehrnaz Valadan; Monica Diczbalis; Jake Olivier; Geoff Otton; André Fedier; Neville F Hacker; James P Scurry
Journal:  Int J Mol Med       Date:  2014-02-14       Impact factor: 4.101

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.